EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Virological outcomes, resistance profile and viral evolution of lenacapavir-based regimens in heavily treatment-experienced people: data from the PRESTIGIO Registry

Maria Mercedes Santoro, Daniele Spalletta iD, Vincenzo Spagnuolo iD, Chiara Paletti, Greta Marchegiani, Maria Concetta Bellocchi, Riccardo Lolatto, Luca Carioti iD, Adriana Cervo iD, Antonio Di Biagio, Marta Fiscon, Emanuele Focà iD und 8 weitere

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag335 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Maria Mercedes Santoro und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, University of Rome 'Tor Vergata', Via Montpellier 1, Rome 00133, Italy. Hauptthemen laut MEDLINE: HIV-1, Drug Resistance, Viral, HIV Infections, Anti-HIV Agents. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lenacapavir (LEN) is a first-in-class, long-acting HIV-1 capsid inhibitor, approved for the treatment of heavily treatment-experienced (HTE) people with HIV (PWH) with multidrug resistance (MDR). To date, few data are available on resistance profiles in real life.

Methods

Paired plasma and PBMC samples from nine HTE PWH with MDR enrolled in the PRESTIGIO Registry receiving LEN in combination with an optimized background regimen were collected before (baseline) and during LEN treatment. Next-generation sequencing was performed using in-house protocols. LEN susceptibility was assessed by single-cycle assay. Intra-patient viral evolution was evaluated through quasispecies distance analysis.

Results

At baseline, no major LEN resistance-associated mutations were detected; the accessory capsid polymorphism T107A was identified as a minority variant (5.9%) in one case, with phenotypic assays confirming full LEN susceptibility (mean fold-change: 1.2). Participants received LEN for a median [IQR] of 19.8 [18.5–23.2] months. Two individuals started LEN with undetectable viremia and maintained suppression. The other seven participants were viremic; six achieved viral suppression, with one experiencing a blip. One low-adherent participant exhibited persistent viremia with Q67K and K70H as the majority variants in both plasma (98.5%; 97.8%) and PBMCs (75.7%; 75.6%), conferring a 2081-fold reduction in LEN susceptibility. Intra-host variability in the capsid and pol regions remained low over time and across compartments.

Conclusions

In this case series of HTE PWH with MDR, LEN was highly associated with maintenance or achievement of virological suppression and limited virus evolution, with only one participant remaining viremic and showing a majority highly LEN-resistant variant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1Drug Resistance, ViralHIV InfectionsAnti-HIV AgentsEvolution, MolecularHumansRegistriesMaleFemaleTreatment OutcomeHigh-Throughput Nucleotide SequencingMiddle AgedAdultLeukocytes, MononuclearMutationAcetamidesIndazoles

Substanzen

Anti-HIV AgentslenacapavirAcetamidesIndazoles

Autor:innen und Institutionen

  • Department of Experimental Medicine, University of Rome 'Tor Vergata', Via Montpellier 1, Rome 00133, Italy.
  • Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Department of Medical Biotechnologies, University of Siena, Siena, Italy.
  • Infectious Disease Clinic, University of Modena and Reggio Emilia, AOU Policlinico di Modena, Modena, Italy.
  • Infectious Diseases Unit, San Martino Hospital Genoa, University of Genoa, Genoa, Italy.
  • Infectious Diseases Unit, Azienda Scaligera di Verona, Verona, Italy.

ORCID-Profile: Daniele Spalletta, Vincenzo Spagnuolo, Luca Carioti, Adriana Cervo, Emanuele Focà, Stefano Rusconi, Maurizio Zazzi, Antonella Castagna, Francesco Saladini

Förderung

  • ViiV Healthcare
  • Gilead Sciences

Zitieren

APA

Santoro, M. M., Spalletta, D., Spagnuolo, V., Paletti, C., Marchegiani, G., Bellocchi, M. C., Lolatto, R., Carioti, L., Cervo, A., Di Biagio, A., Fiscon, M., Focà, E., Gagliardini, R., Rusconi, S., Zazzi, M., Castagna, A., Saladini, F., Ceccherini-Silberstein, F., PRESTIGIO Registry, & the (2026). Virological outcomes, resistance profile and viral evolution of lenacapavir-based regimens in heavily treatment-experienced people: data from the PRESTIGIO Registry. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag335

Vancouver

Santoro MM, Spalletta D, Spagnuolo V, Paletti C, Marchegiani G, Bellocchi MC, et al. Virological outcomes, resistance profile and viral evolution of lenacapavir-based regimens in heavily treatment-experienced people: data from the PRESTIGIO Registry. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag335

BibTeX
@article{Santoro2026,
  author = {Santoro, Maria Mercedes and Spalletta, Daniele and Spagnuolo, Vincenzo and Paletti, Chiara and Marchegiani, Greta and Bellocchi, Maria Concetta and Lolatto, Riccardo and Carioti, Luca and Cervo, Adriana and Di Biagio, Antonio and Fiscon, Marta and Focà, Emanuele and Gagliardini, Roberta and Rusconi, Stefano and Zazzi, Maurizio and Castagna, Antonella and Saladini, Francesco and Ceccherini-Silberstein, Francesca and PRESTIGIO Registry, PRESTIGIO Registry and the, the},
  title = {Virological outcomes, resistance profile and viral evolution of lenacapavir-based regimens in heavily treatment-experienced people: data from the PRESTIGIO Registry},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag335}
}
Kostenlos starten →